What happened
Retractable Technologies, Inc. (NYSE American: RVP) said on September 30, 2026 that its board declared dividends on Series II Class B Convertible Preferred Stock and Series III Class B Convertible Preferred Stock. The amounts are $39,050.00 and $18,561.25, respectively.
The press release came from Little Elm, Texas, on September 30, 2026. The dividends accrued at $1.00 per share per annum and cover July 1, 2026 through September 30, 2026. Retractable said it will pay them on October 22, 2026 to shareholders of record as of the close of business on October 12, 2026.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Series II Class B Convertible Preferred Stock dividend | $39,050.00 | SEC 8-K | |
| Series III Class B Convertible Preferred Stock dividend | $18,561.25 | SEC 8-K | |
| Dividend accrual rate | $1.00 per share per annum | SEC 8-K | |
| Series II dividend to Series III dividend ratio | 2.10x | Calculated from SEC 8-K |
Why it matters
OptimistFi's case is that RVP is a turnaround option on differentiated safety syringes, but value depends on hospital demand turning into positive gross margin and cash before liquidity or dilution binds. This filing leaves that case unchanged because it is a preferred-dividend declaration, not an operating update.
The payment is a cash obligation on Series II and Series III Class B Convertible Preferred Stock, and the Series II amount is about 2.10x the Series III amount. That comparison helps size the near-term cash outlay tied to the preferred stock, while the press release says the dividends accrued at $1.00 per share per annum.
Retractable Technologies, Inc. also says it manufactures and markets VanishPoint, Patient Safe and EasyPoint, and distributes its products through various specialty and general line distributors. VanishPoint syringe, blood collection and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient.
Patient Safe syringes are designed to reduce bloodstream infections from catheter hub contamination, and EasyPoint can be used with luer lock syringes, luer slip syringes and prefilled syringes. Those details matter because the turnaround still depends on product demand and cash generation, not this preferred dividend.
It is a capital obligation, not evidence that hospital demand or gross margin improved.
Browse: stock research on every company OptimistFi covers
What's next
The next dated milestone is the close of business on October 12, 2026, the record date for the dividends. Payment follows on October 22, 2026.
If Retractable pays on October 22, 2026 as stated, the filing's capital obligation will have been carried out as announced. The filing's dates give investors a concrete check on whether the declared preferred dividend is delivered on schedule.
That would keep the event confined to the capital side of the story, while the operating case still turns on product demand, gross margin and cash.
More from OptimistFi
- RVP stock: the Retractable Technologies thesis, its status and the next test to watch
- Rogers Corporation (NYSE: ROG) Targets $1.5 Billion in Sales
- Eli Lilly and Company (NYSE: LLY) EloraTZP Adds Weight Loss and More Dropouts
- Momentus Inc. (NASDAQ: MNTS) Completes NASA Satellite Test
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC 8-K exhibit 99 press release — Press release declaring dividends on Series II and Series III Class B Convertible Preferred Stock.
- SEC Form 8-K — Current report stating the company issued the dividend announcement on September 30, 2026.
Read the full OptimistFi thesis on Retractable Technologies, Inc.: https://optimistfi.com/stocks/RVP
See what would break the Retractable Technologies, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Retractable Technologies, Inc. investment case, its status and the next test to watch live on the Retractable Technologies, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
